RESULTS	This dose also resulted in a lower incidence of acute exacerbations , as compared with placebo ( 2.4 vs. 15.7 per 100 patient-years , P = 0.02 ) and a small decrease in the SGRQ score ( assessed on a scale of 0 to 100 , with lower scores indicating better quality of life ) as compared with an increase with placebo ( -0.66 vs. 5.46 , P = 0.007 ) .\